ASTRAZENECA PLC |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 12,346 GBX | +1.28% |
|
+0.41% | +16.47% |
| 03/06 | Global markets live: GSK, Walt Disney, Blackstone, Boeing, Microsoft... |  |
| 03/06 | ASTRAZENECA : JP Morgan remains its Buy rating | ZD |
| Sales 2024 * | 51.62B 4,288B | Sales 2025 * | 55.5B 4,610B | Capitalization | 245B 20,332B |
|---|---|---|---|---|---|
| Net income 2024 * | 8.84B 735B | Net income 2025 * | 10.38B 862B | EV / Sales 2024 * | 5.14 x |
| Net Debt 2024 * | 20.42B 1,696B | Net Debt 2025 * | 13.71B 1,139B | EV / Sales 2025 * | 4.66 x |
| P/E ratio 2024 * |
27.9
x | P/E ratio 2025 * |
23.7
x | Employees | 89,900 |
| Yield 2024 * |
1.95% | Yield 2025 * |
2.05% | Free-Float | 96.62% |
More Fundamentals
* Assessed data
More news
Latest transcript on AstraZeneca PLC
More recommendations
More press releases
| 1 day | +1.28% | ||
| 1 week | +0.41% | ||
| Current month | +1.28% | ||
| 1 month | +1.56% | ||
| 3 months | +22.48% | ||
| 6 months | +21.06% | ||
| Current year | +16.47% |
1 week
11 858.00
12 380.00
1 month
11 858.0012 450.00
Current year
9 461.0012 488.00
1 year
9 461.0012 488.00
3 years
7 924.0012 488.00
5 years
5 871.0012 488.00
10 years
3 680.0012 488.00
| Managers | Title | Age | Since |
|---|---|---|---|
Pascal Soriot
CEO | Chief Executive Officer | 64 | 01/12/01 |
Aradhana Sarin
DFI | Director of Finance/CFO | 50 | 01/21/01 |
Sharon Barr
CTO | Chief Tech/Sci/R&D Officer | - | 01/23/01 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Sherilyn McCoy
BRD | Director/Board Member | 65 | 01/17/01 |
Philip Broadley
BRD | Director/Board Member | 63 | 27/17/27 |
| Director/Board Member | 68 | 01/99/01 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 9.20% | 11 M€ | +0.83% | - | |
| 5.39% | 200 M€ | +16.52% | ||
| 5.17% | 17 M€ | +7.32% | - | |
| 4.89% | 693 M€ | +12.81% |
| Date | Price | Change | Volume |
|---|---|---|---|
| 03/24/03 | 12,346 | +1.28% | 1,630,083 |
| 31/24/31 | 12,190 | +1.35% | 4,183,291 |
| 30/24/30 | 12,028 | +0.82% | 1,694,794 |
| 29/24/29 | 11,930 | -0.81% | 2,028,915 |
Delayed Quote London S.E., June 03, 2024 at 09:05 pm IST
More quotes
AstraZeneca PLC is one of the world's leading pharmaceutical groups. Net sales break down by source of income as follows:
- product sales (95.6%). Net sales break down by treatment area between oncology (39.2%), cardiovascular, renal and metabolic diseases (24.2%), respiratory and autoimmune diseases (13.9%), and other (22.7%; inflammatory diseases, neurological diseases, gastrointestinal and infectious diseases);
- collaboration revenue (4.4%).
Net sales are distributed geographically as follows: the United Kingdom (7.4%), Europe (21.2%), America (45.3%) and Africa-Asia-Australia (26.1%).
Sector
Pharmaceuticals
Calendar
06:00am
- Investor Meeting
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
B+
Sell
Buy
Mean consensus
BUY
Number of Analysts
23
Last Close Price
157.9
USD
Average target price
172
USD
Spread / Average Target
+8.94%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +16.47% | 240B | |
| +42.60% | 739B | |
| +32.34% | 598B | |
| -5.74% | 353B | |
| +17.79% | 318B | |
| +3.37% | 285B | |
| +9.26% | 210B | |
| -5.07% | 206B | |
| +6.74% | 164B | |
| +1.81% | 162B |
- Stock Market
- Equities
- AZN Stock
